Hyperlipidemias
Conditions
Keywords
Statin, LDL-C
Brief summary
The primary objective is to survey the efficacy of various commercially available statins (a class of lipid-lowering agents, for example, rosuvastatin, atorvastatin, simvastatin, lovastatin, pravastatin and fluvastatin) under local clinical practice in treating patients with hyperlipidemia. Surveillance data (Lipid Profile) will be collected during course of usual clinical practice or captured upon its availability.
Interventions
None listed
Sponsors
AstraZeneca
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* patients diagnosed with hyperlipidemia * Patients who are just starting a statin treatment, who need to switch from current therapy to a statin medication, or who are receiving dosage adjustment of statin as judged by the physicians * Patients who are willing to participate in this study and who sign an informed consent form
Exclusion criteria
* Pregnancy or breast feeding * Patient are illiterate or unable to fill the questionnaire for any reason * Patients with contraindications to the use of certain statins as needed prescribed by physicians (as per commercially available statins package insert) including the use of rosuvastatin. * Any clinical condition which, in the opinion of the attending physician, would not allow safe administration of the study medications
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes on LDL-C, HDL-C, TG, TC | 3~6 months |
Secondary
| Measure | Time frame |
|---|---|
| ratio for treatment-to-goal | 3~6 months |
| drug compliance | 3~6 months |
| correlation between patient's insight and therapeutic outcome | 3~6 months |
Countries
Taiwan
Outcome results
None listed